These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32852528)

  • 41. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identifying appropriate patients for early salvage radiotherapy after prostatectomy.
    Karlin JD; Koontz BF; Freedland SJ; Moul JW; Grob BM; Wan W; Hagan MP; Anscher MS; Moghanaki D
    J Urol; 2013 Oct; 190(4):1410-5. PubMed ID: 23648223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.
    Spiotto MT; Hancock SL; King CR
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):54-61. PubMed ID: 17459606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients.
    Soto DE; Passarelli MN; Daignault S; Sandler HM
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1227-32. PubMed ID: 21549519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy.
    D'Amico AV; Whittington R; Malkowicz SB; Loughlin K; Schultz D; Schnall M; Tempany CM; Tomaszewski JE; Renshaw A; Wein A
    Urology; 1996 Apr; 47(4):538-47. PubMed ID: 8638365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement.
    Freedland SJ; Rumble RB; Finelli A; Chen RC; Slovin S; Stein MN; Mendelson DS; Wackett C; Sandler HM;
    J Clin Oncol; 2014 Dec; 32(34):3892-8. PubMed ID: 25366677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiotherapy after radical prostatectomy: immediate or early delayed?
    Bottke D; Bartkowiak D; Schrader M; Wiegel T
    Strahlenther Onkol; 2012 Dec; 188(12):1096-101. PubMed ID: 23128897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Salvage radiation therapy following radical prostatectomy. A national Danish study.
    Ervandian M; Høyer M; Petersen SE; Sengeløv L; Hansen S; Holmberg M; Sveistrup J; Meidahl Petersen P; Borre M
    Acta Oncol; 2016 May; 55(5):598-603. PubMed ID: 26399602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis.
    Sheets NC; Hendrix LH; Allen IM; Chen RC
    Cancer; 2013 Sep; 119(18):3295-301. PubMed ID: 23842985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Spratt DE; Dess RT; Zumsteg ZS; Lin DW; Tran PT; Morgan TM; Antonarakis ES; Nguyen PL; Ryan CJ; Sandler HM; Cooperberg MR; Posadas E; Feng FY
    Eur Urol; 2018 Feb; 73(2):156-165. PubMed ID: 28716370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.